292 related articles for article (PubMed ID: 17597608)
1. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.
Schumacher WA; Seiler SE; Steinbacher TE; Stewart AB; Bostwick JS; Hartl KS; Liu EC; Ogletree ML
Eur J Pharmacol; 2007 Sep; 570(1-3):167-74. PubMed ID: 17597608
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
[TBL] [Abstract][Full Text] [Related]
3. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits.
Wong PC; Crain EJ; Watson CA; Schumacher WA
J Thromb Thrombolysis; 2011 Aug; 32(2):129-37. PubMed ID: 21614454
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
7. In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa.
Wong PC; Quan ML; Watson CA; Crain EJ; Harpel MR; Rendina AR; Luettgen JM; Wexler RR; Schumacher WA; Seiffert DA
J Thromb Thrombolysis; 2015 Nov; 40(4):416-23. PubMed ID: 26249722
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
9. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
[TBL] [Abstract][Full Text] [Related]
10. Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis.
Schumacher WA; Bostwick JS; Stewart AB; Steinbacher TE; Xin B; Wong PC
J Cardiovasc Pharmacol; 2010 Jun; 55(6):609-16. PubMed ID: 20224421
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Suleymanov OD; Szalony JA; Salyers AK; LaChance RM; Parlow JJ; South MS; Wood RS; Nicholson NS
J Pharmacol Exp Ther; 2003 Sep; 306(3):1115-21. PubMed ID: 12829728
[TBL] [Abstract][Full Text] [Related]
12. A human antibody that binds to the gamma-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo.
Refino CJ; Himber J; Burcklen L; Moran P; Peek M; Suggett S; Devaux B; Kirchhofer D
Thromb Haemost; 1999 Sep; 82(3):1188-95. PubMed ID: 10494786
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Stassen JM; Lambeir AM; Vreys I; Deckmyn H; Matthyssens G; Nyström A; Vermylen J
Thromb Haemost; 1995 Aug; 74(2):655-9. PubMed ID: 8585002
[TBL] [Abstract][Full Text] [Related]
14. The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Cho JH; Yun CH; Seo HS; Koga T; Dan T; Koo BA; Kim HY
Thromb Haemost; 2001 Dec; 86(6):1512-20. PubMed ID: 11776321
[TBL] [Abstract][Full Text] [Related]
15. BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.
Wong PC; Luettgen JM; Rendina AR; Kettner CA; Xin B; Knabb RM; Wexler R; Priestley ES
Thromb Haemost; 2010 Aug; 104(2):261-9. PubMed ID: 20589312
[TBL] [Abstract][Full Text] [Related]
16. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
18. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
Wong PC; Crain EJ; Bozarth JM; Wu Y; Dilger AK; Wexler RR; Ewing WR; Gordon D; Luettgen JM
J Thromb Haemost; 2022 Feb; 20(2):399-408. PubMed ID: 34752670
[TBL] [Abstract][Full Text] [Related]
19. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit.
Bostwick JS; Bentley R; Morgan S; Brown K; Chu V; Ewing WR; Spada AP; Pauls H; Perrone MH; Dunwiddie CT; Leadley RJ
Thromb Haemost; 1999 Jan; 81(1):157-60. PubMed ID: 10348709
[TBL] [Abstract][Full Text] [Related]
20. The effect of taurolidine on experimental thrombus formation.
Kaptanoglu L; Kucuk HF; Colak E; Kurt N; Bingul SM; Akyol H; Torlak OA; Yazici F
Eur J Pharmacol; 2008 Jan; 578(2-3):238-41. PubMed ID: 17961549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
